Cancer experts provide leading treatment for myelodysplastic syndromes patients

Myelodysplastic syndromes (MDS) are a group of diseases that affect the blood and bone marrow. In MDS, normal blood-forming processes slow down, failing to produce the healthy cells and platelets crucial to fighting off disease.

The University of Kansas Cancer Center in Kansas City offers specialty care and deep experience – including in revolutionary precision cancer therapies – to help patients fighting MDS achieve the best possible outcomes. The first step in caring for you begins the moment you call.

The body's blood-forming cells are responsible for producing red blood cells, white blood cells and platelets. In MDS, this process slows, leaving the body ill-equipped to pump oxygen throughout the body, fight infections and stop bleeding.

There are numerous types of MDS. Some forms are mild and treatable. Others are severe and dangerous. MDS has the potential to evolve into acute myeloid leukemia, a life-threatening blood cancer.

• The myelodysplastic syndrome experts at The University of Kansas Cancer Center offer experience second to none. All are board-certified in their specialties and provide patients with focused care using the latest in diagnostic and treatment techniques. They bring every resource to addressing patients' physical, mental and emotional needs.
• Our commitment to collaboration extends to community physicians. We are very accustomed and happy to partner with your local physicians so that you can receive as much of your care as possible close to home and your support system.
• The University of Kansas Cancer Center is the region's premier academic medical center and a National Cancer Institute-designated comprehensive cancer center. This culture and these distinctions provide our organization with access to the latest diagnostic and treatment advances, including promising clinical trials. This gives our patients the most hope and the most options in pursuing a return to good health.